Literature DB >> 19647595

Cutaneous melanoma in the era of molecular profiling.

John F Thompson1, Richard A Scolyer, Richard F Kefford.   

Abstract

Entities:  

Mesh：

Year:  2009        PMID： 19647595     DOI： 10.1016/S0140-6736(09)61397-0

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  36 in total

1.  Rendomab B4, a monoclonal antibody that discriminates the human endothelin B receptor of melanoma cells and inhibits their migration.

Authors:  Aurélie Borrull; Bertrand Allard; Anne Wijkhuisen; Amaury Herbet; Patricia Lamourette; Wided Birouk; Denis Leiber; Zahra Tanfin; Frédéric Ducancel; Didier Boquet; Jean-Yves Couraud; Philippe Robin
Journal:  MAbs       Date:  2016-07-08       Impact factor: 5.857

2.  Genetic and morphologic features for melanoma classification.

Authors:  Sigrid M C Broekaert; Ritu Roy; Ichiro Okamoto; Joost van den Oord; Jürgen Bauer; Claus Garbe; Raymond L Barnhill; Klaus J Busam; Alistair J Cochran; Martin G Cook; David E Elder; Stanley W McCarthy; Martin C Mihm; Dirk Schadendorf; Richard A Scolyer; Alan Spatz; Boris C Bastian
Journal:  Pigment Cell Melanoma Res       Date:  2010-12       Impact factor: 4.693

3.  Suppression of Type I Interferon Signaling Overcomes Oncogene-Induced Senescence and Mediates Melanoma Development and Progression.

Authors:  Yuliya V Katlinskaya; Kanstantsin V Katlinski; Qiujing Yu; Angelica Ortiz; Daniel P Beiting; Angela Brice; Diwakar Davar; Cindy Sanders; John M Kirkwood; Hallgeir Rui; Xiaowei Xu; Constantinos Koumenis; J Alan Diehl; Serge Y Fuchs
Journal:  Cell Rep       Date:  2016-03-24       Impact factor: 9.423

Review 4.  Sentinel lymph node biopsy followed by lymph node dissection for localised primary cutaneous melanoma.

Authors:  Athanassios Kyrgidis; Thrasivoulos Tzellos; Simone Mocellin; Zoe Apalla; Aimilios Lallas; Pierluigi Pilati; Alexander Stratigos
Journal:  Cochrane Database Syst Rev       Date:  2015-05-16

Review 5.  Evolving concepts in melanoma classification and their relevance to multidisciplinary melanoma patient care.

Authors:  Richard A Scolyer; Georgina V Long; John F Thompson
Journal:  Mol Oncol       Date:  2011-03-21       Impact factor: 6.603

6.  Pitfalls and important issues in the pathologic diagnosis of melanocytic tumors.

Authors:  Stanley W McCarthy; Richard A Scolyer
Journal:  Ochsner J       Date:  2010

7.  Comprehensive assessment of the association of ERCC2 Lys751Gln polymorphism with susceptibility to cutaneous melanoma.

Authors:  Yuhao Dong; Le Zhuang; Weiyuan Ma
Journal:  Tumour Biol       Date:  2013-02-03

8.  A randomized, double-blind, placebo-controlled study of high-dose bosentan in patients with stage IV metastatic melanoma receiving first-line dacarbazine chemotherapy.

Authors:  Richard F Kefford; Philip R Clingan; Benjamin Brady; Andrea Ballmer; Adele Morganti; Peter Hersey
Journal:  Mol Cancer       Date:  2010-03-30       Impact factor: 27.401

9.  Melanoma: Stem cells, sun exposure and hallmarks for carcinogenesis, molecular concepts and future clinical implications.

Authors:  Athanassios Kyrgidis; Thrasivoulos-George Tzellos; Stefanos Triaridis
Journal:  J Carcinog       Date:  2010-04-01

10.  Inhibition of melanoma growth by subcutaneous administration of hTERTC27 viral cocktail in C57BL/6 mice.

Authors:  Longfei Huo; Hong Yao; Xicai Wang; Gee Wan Wong; Hsiang-fu Kung; Marie C Lin
Journal:  PLoS One       Date:  2010-09-13       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.